{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:27:18Z","timestamp":1740108438815,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00296-019-04256-1","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T06:18:50Z","timestamp":1551161930000},"page":"1019-1025","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Power-Doppler perfusion phenotype in RA patients is dependent on anti-citrullinated peptide antibody status, not on rheumatoid factor"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6320-4818","authenticated-orcid":false,"given":"O.","family":"Gadeholt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8028-8099","authenticated-orcid":false,"given":"M.","family":"Feuchtenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2813-7100","authenticated-orcid":false,"given":"T.","family":"Wech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1935-2092","authenticated-orcid":false,"given":"E. C.","family":"Schwaneck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"key":"4256_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/ard.2005.044354","volume":"66","author":"B Combe","year":"2007","unstructured":"Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, Emery P, Ferraccioli G, Hazes JM, Klareskog L, Machold K, Martin-Mola E, Nielsen H, Smolen J, Yazici H (2007) EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66:34\u201345","journal-title":"Ann Rheum Dis"},{"key":"4256_CR2","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1136\/annrheumdis-2014-205428","volume":"74","author":"C Hecht","year":"2015","unstructured":"Hecht C, Englbrecht M, Rech J, Schmidt S, Araujo E, Engelke K, Finzel S, Schett G (2015) Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Ann Rheum Dis 74:2151\u20132156","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4256_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.berh.2014.10.016","volume":"28","author":"AG Pratt","year":"2014","unstructured":"Pratt AG, Isaacs JD (2014 Aug) Seronegative rheumatoid arthritis: pathogenic and therapeutic aspects. Best Pract Res Clin Rheumatol 28(4):651\u2013659","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"4256_CR4","volume-title":"Kelley\u2019s textbook of rheumatology","author":"ED Harris Jr","year":"2009","unstructured":"Harris ED Jr, Firestein GS (2009) Clinical features of rheumatoid arthritis. In: Firestein GS, Budd RC, Harris ED Jr, McInnes IB, Ruddy S, Sergent JS (eds) Kelley\u2019s textbook of rheumatology, 8th edn. Elsevier, Philadelphia","edition":"8"},{"issue":"3","key":"4256_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","volume":"72","author":"JD Isaacs","year":"2013","unstructured":"Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G, Williams S, Lal P, Read SJ (2013) Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 72(3):329\u2013336","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4256_CR6","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/art.39595","volume":"68","author":"JE Gottenberg","year":"2016","unstructured":"Gottenberg JE, Courvoisier DS, Hernandez MV, Iannone F, Lie E, Canh\u00e3o H, Pavelka K, Hetland ML, Turesson C, Mariette X, Finckh (2016) A brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the pan-european registry analysis. Arthritis Rheumatol 68(6):1346\u20131352","journal-title":"Arthritis Rheumatol"},{"key":"4256_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1136\/ard.2009.126821","volume":"70","author":"L Padyukov","year":"2011","unstructured":"Padyukov L, Seielstad M, Ong RT, Ding B, R\u00f6nnelid J, Seddighzadeh M, Alfredsson L, Klareskog L (2011) Epidemiological investigation of rheumatoid arthritis (EIRA) study group: a genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis 70:259\u2013265","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 104","key":"4256_CR8","first-page":"20","volume":"35","author":"O Gadeholt","year":"2017","unstructured":"Gadeholt O (2017) Rheumatoid arthritis is not a single disease. Clin Exp Rheumatol 35(Suppl 104(2):20\u201321","journal-title":"Clin Exp Rheumatol"},{"key":"4256_CR9","doi-asserted-by":"publisher","first-page":"R180","DOI":"10.1186\/ar3505","volume":"13","author":"DP Rooy De","year":"2011","unstructured":"De Rooy DP, Willemze A, Mertens B, Huizinga TWJ van der (2011) Helm-van Mil AHM: can anti-cyclic citrullinated peptide antibody-negative RA be subdivided into clinical subphenotypes? Arthritis Res Ther 13:R180","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"4256_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.archger.2005.07.003","volume":"42","author":"N Turkcapar","year":"2006","unstructured":"Turkcapar N, Demir O, Atli T, Kopuk M, Turgay M, Kinikli G, Duman M (2006) Late onset rheumatoid arthritis: clinical and laboratory comparisons with younger onset patients. Arch Gerontol Geriatr 42(2):225\u2013231","journal-title":"Arch Gerontol Geriatr"},{"key":"4256_CR11","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1136\/annrheumdis-2017-211325","volume":"76","author":"LE Burgers","year":"2017","unstructured":"Burgers LE, van Steenbergen HW, ten Brinck RM, Huizinga TW van der (2017) Helm-van Mil AH: Differences in the symptomatic phase preceding ACPA-positive and ACPA-negative RA: a longitudinal study in arthralgia during progression to clinical arthritis. Ann Rheum Dis 76:1751\u20131754","journal-title":"Ann Rheum Dis"},{"key":"4256_CR12","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1136\/ard.42.6.605","volume":"42","author":"TM Burns","year":"1983","unstructured":"Burns TM, Calin A (1983) The hand radiograph as a diagnostic discriminant between seropositive and seronegative \u2018rheumatoid arthritis\u2019: a controlled study. Ann Rheum Dis 42:605\u2013612","journal-title":"Ann Rheum Dis"},{"key":"4256_CR13","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, M\u00e9nard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580\u20131588","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4256_CR14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1093\/rheumatology\/keg184","volume":"42","author":"S Bas","year":"2003","unstructured":"Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 42(5):677\u2013680","journal-title":"Rheumatology"},{"issue":"1","key":"4256_CR15","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1136\/annrheumdis-2014-206631","volume":"74","author":"C Hecht","year":"2015","unstructured":"Hecht C, Schett G, Finzel S (2015) The impact of rheumatoid factor and ACPA on bone erosion in rheumatoid arthritis. Ann Rheum Dis 74(1):e4","journal-title":"Ann Rheum Dis"},{"key":"4256_CR16","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00296-016-3548-6","volume":"36","author":"O Gadeholt","year":"2016","unstructured":"Gadeholt O, Wech T, Schuh S, Scharbatke EC, Ostermeier E, Tony HP, Schmalzing M (2016) Anti-CCP status determines the power Doppler oscillation pattern in rheumatoid arthritis: a prospective study. Rheumatol Int 36:1671\u20131675","journal-title":"Rheumatol Int"},{"key":"4256_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u2013324","journal-title":"Arthritis Rheum"},{"issue":"1","key":"4256_CR18","doi-asserted-by":"publisher","first-page":"e000428","DOI":"10.1136\/rmdopen-2016-000428","volume":"11","author":"M-A D\u2019Agostino","year":"2017","unstructured":"D\u2019Agostino M-A, Terslev L, Aegerter P, Backhaus M, Balint P, Bruyn GA, Filippucci E, Grassi W, Iagnocco A, Jousse-Jolin S, Kane D, Naredo E, Schmidt W, Szkudlarek M, Conaghan PG, Wakefield RJ (2017) Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce\u2014part 1: definition and development of a standardised, consensus-based scoring system. RMD Open 11(1):e000428 3(","journal-title":"RMD Open"},{"key":"4256_CR19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/art.1780040602","volume":"4","author":"C Ragan","year":"1961","unstructured":"Ragan C (1961) The history of the rheumatoid factor. Arthritis Rheum 4:571\u2013573","journal-title":"Arthritis Rheum"},{"key":"4256_CR20","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/art.1780080408","volume":"8","author":"SD Litwin","year":"1965","unstructured":"Litwin SD, Singer JM (1965) Studies of the incidence and significance of anti-gamma globulin factors in the aging. Arthritis Rheum 8:538\u2013550","journal-title":"Arthritis Rheum"},{"issue":"2","key":"4256_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.semarthrit.2017.04.009","volume":"47","author":"D Boeters","year":"2017","unstructured":"Boeters D, Gaujoux-Viala C, Constantin A, van der Helm-van Mil AHM (2017) The 2010 ACR\/EULAR criteria are not sufficiently accurate in the early identification of autoantibody-negative rheumatoid arthritis: Results from the Leiden-EAC and ESPOIR cohorts. Semin Arthritis Rheum 47(2):170\u2013174","journal-title":"Semin Arthritis Rheum"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-019-04256-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04256-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04256-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T19:13:48Z","timestamp":1582658028000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-019-04256-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,26]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["4256"],"URL":"https:\/\/doi.org\/10.1007\/s00296-019-04256-1","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"type":"print","value":"0172-8172"},{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2019,2,26]]},"assertion":[{"value":"12 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"OG: speaker\u2019s fees from Abbvie, Chugai, Janssen-Cilag, Novartis, and Sanofi. Grants from Abbvie, Chugai, Janssen-Cilag, Lilly, Novartis and Roche. Advisory board participation for Novartis. All outside the submitted work. MF: personal Fees from Abbvie, Chugai, Janssen-Cilag MSD, Pfizer, Roche and UCB. All outside the submitted work. TW: research grant from Siemens Healthcare. Outside the submitted work. ECS: speaker\u2019s fees from Abbvie, Chugai, Jansen-Cilag, Lilly, Novartis and Shire. Grants from Abbvie, Celgene, Chugai, Novartis and Shire. All outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Final approval by the ethics committee of the University of W\u00fcrzburg, W\u00fcrzburg, Germany 20.07.2018 (Protocol Number 22\/18). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"No application was submitted to the ethics commission of the University of W\u00fcrzburg for permission to share the obtained data. Hence, the data cannot be made available for further analysis.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}}]}}